With vaccine success, scientists turn mRNA into autoimmune disease

What is that?

STAT + is STAT’s premium subscription service for in-depth coverage and analysis in biotechnology, pharmacy, policy, and life sciences. Our award-winning team covers Wall Street news, political developments in Washington, early scientific breakthroughs and clinical trial results, and healthcare disruptions in Silicon Valley and beyond.

What’s included?

• Daily reports and analyzes
• Industry’s most comprehensive coverage by a team of powerful journalists
• Subscriber newsletters
• Daily newsletters to keep you informed about the most important news in the sector
• STAT + conversations
• Weekly opportunities to engage with our journalists and leading industry experts in live video chats
• Exclusive industry events
• Premium access to subscriber-only networking events nationwide
• The best reporters in the industry
• The most reliable and most connected newsroom in the healthcare industry
• And much more
• Exclusive interviews with industry leaders, profiles and high-end tools, like our CRISPR Trackr.